Cabazitaxel
Based on 26 publication(s) in Google Scholar
Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.98%
- CAS No.: 183133-96-2
- Formule: C45H57NO14
- Masse moléculaire:835.93
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Natural Product Library
HY-L021
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
CNS-Penetrant Compound Library
HY-L028
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Macrocyclic Compound Library
HY-L041
-
Cytoskeleton Compound Library
HY-L060
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Lung Cancer Compound Library
HY-L075
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Targeted Therapy Drug Library
HY-L080
-
Anti-Cancer Natural Product Library
HY-L107
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Chemotherapy Drug Library
HY-L112
-
Plant-Sourced Natural Product Library
HY-L115
-
EMA-Approved Drug Library
HY-L116
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Cell Death Library
HY-L162
-
FDA-Approved Traditional Chinese Medicine Active Compound Library
HY-L163
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Miao Ethnicity Medicine Compound Library
HY-L190
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Anti-Cancer Approved Drug Library
HY-L213
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
High-Efficiency Gene Editing Compound Library
HY-L244
-
Natural Product Diversity Scaffold Library
HY-L245
-
Classic FDA-Approved Drug Library
HY-L261
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Cabazitaxel
More- Eur Urol. 2020 Nov 2;S0302-2838(20)30778-8. [Abstract]
- J Clin Invest. 2026 Mar 17:e200260. [Abstract]
- Cell Rep Med. 2025 Apr 2:102053. [Abstract]
- Proc Natl Acad Sci U S A. 2025 Nov 18;122(46):e2503094122. [Abstract]
- Pharmaceutics. 2023 Feb 16;15(2):662. [Abstract]
- ACS Appl Nano Mater. 2019 Oct 25;2(10):6249-6257. [Abstract]
- Microchem J. 2025 Oct 15;218:115702.
- RSC Adv. 2023 Apr 6;13(16):10923-10939. [Abstract]
- Nanomedicine (Lond). 2017 Sep;12(17):2083-2095. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- Mol Pharm. 2022 Nov 7;19(11):4320-4332. [Abstract]
- Sci Rep. 2023 Jun 3;13(1):9043. [Abstract]
- J Pharm Sci. 2025 May;114(5):103708. [Abstract]
- Cardiovasc Toxicol. 2026 May 27;26(6):61. [Abstract]
- Bioengineering (Basel). 2025 Oct 19;12(10):1121. [Abstract]
- Cancer Manag Res. 2020 Oct 29;12:10809-10820. [Abstract]
- PLoS One. 2020 Jun 2;15(6):e0234078. [Abstract]
- Prostate. 2018 Sep;78(12):905-914. [Abstract]
- Prostate. 2018 Feb;78(3):166-177. [Abstract]
- bioRxiv. 2026 Mar 18.
- bioRxiv. 2026 Jan 19.
- Patent. US20220211630A1.
- Patent. US20220008350A1.
- Methods Mol Biol. 2018:1711:351-398. [Abstract]
- Oncotarget. 2016 May 17;7(20):28891-902. [Abstract]
- Chin J Cancer. 2015 Mar 5;34(3):115-20. [Abstract]
Customer Validation & Images
-
Cell Imaging/Staining
-
Cell Proliferation/Viability Assay
-
Cell Migration/Invasion Assay
-
ELISA
-
Cell Proliferation/Viability Assay
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-431 | GI50 |
1.483 nM
Compound: 3
|
Growth inhibition of human A431 cells by MTT assay
Growth inhibition of human A431 cells by MTT assay
|
[PMID: 24405702] |
| A549 | GI50 |
1.483 nM
Compound: 3
|
Growth inhibition of human A549 cells by MTT assay
Growth inhibition of human A549 cells by MTT assay
|
[PMID: 24405702] |
| A549 | IC50 |
1.48 nM
Compound: 9
|
Cytotoxicity against human A549 cells
Cytotoxicity against human A549 cells
|
[PMID: 28850227] |
| A549 | IC50 |
15 nM
Compound: Cabazitaxel
|
Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
|
[PMID: 34058663] |
| A549/TR | IC50 |
62.5 nM
Compound: Cabazitaxel
|
Cytotoxicity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
Cytotoxicity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
|
[PMID: 34058663] |
| BGC-823 | GI50 |
467.2 nM
Compound: 3
|
Growth inhibition of human BGC823 cells by MTT assay
Growth inhibition of human BGC823 cells by MTT assay
|
[PMID: 24405702] |
| DU-145 | GI50 |
1.429 nM
Compound: 3
|
Growth inhibition of human DU145 cells by MTT assay
Growth inhibition of human DU145 cells by MTT assay
|
[PMID: 24405702] |
| HCT-116 | IC50 |
0.029 μM
Compound: 22; CBT
|
Antiproliferative activity against human HCT-116 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells measured after 48 hrs by MTT assay
|
[PMID: 38142509] |
| HCT-8 | IC50 |
0.532 μM
Compound: 22; CBT
|
Antiproliferative activity against human HCT-8 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human HCT-8 cells measured after 48 hrs by MTT assay
|
[PMID: 38142509] |
| HeLa | GI50 |
1.799 nM
Compound: 3
|
Growth inhibition of human HeLa cells by MTT assay
Growth inhibition of human HeLa cells by MTT assay
|
[PMID: 24405702] |
| HL-60 | GI50 |
4.736 nM
Compound: 3
|
Growth inhibition of human HL60 cells by MTT assay
Growth inhibition of human HL60 cells by MTT assay
|
[PMID: 24405702] |
| HT-1080 | GI50 |
1.406 nM
Compound: 3
|
Growth inhibition of human HT1080 cells by MTT assay
Growth inhibition of human HT1080 cells by MTT assay
|
[PMID: 24405702] |
| K562 | GI50 |
4.186 nM
Compound: 3
|
Growth inhibition of human K562 cells by MTT assay
Growth inhibition of human K562 cells by MTT assay
|
[PMID: 24405702] |
| KB | IC50 |
20 nM
Compound: Cabazitaxel
|
Cytotoxicity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
Cytotoxicity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
|
[PMID: 34058663] |
| LoVo | IC50 |
0.063 μM
Compound: 22; CBT
|
Antiproliferative activity against human LoVo cells measured after 48 hrs by MTT assay
Antiproliferative activity against human LoVo cells measured after 48 hrs by MTT assay
|
[PMID: 38142509] |
| MCF7 | GI50 |
1.187 nM
Compound: 3
|
Growth inhibition of human MCF7 cells by MTT assay
Growth inhibition of human MCF7 cells by MTT assay
|
[PMID: 24405702] |
| MES-SA/Dx5 | IC50 |
15 nM
Compound: Cabazitaxel
|
Growth inhibition of human MES-SA/Dx5 cells after 72 hrs by SRB assay
Growth inhibition of human MES-SA/Dx5 cells after 72 hrs by SRB assay
|
[PMID: 29251920] |
| NCI-H524 | IC50 |
0.26 nM
Compound: Cabazitaxel
|
Cytotoxicity in human NCI-H524 cells pre-incubated for 2 hrs followed by compound wash out and subsequently incubated for 70 hrs by Cell Titer Glo assay
Cytotoxicity in human NCI-H524 cells pre-incubated for 2 hrs followed by compound wash out and subsequently incubated for 70 hrs by Cell Titer Glo assay
|
[PMID: 30735385] |
| PANC-1 | GI50 |
1.283 nM
Compound: 3
|
Growth inhibition of human PANC1 cells by MTT assay
Growth inhibition of human PANC1 cells by MTT assay
|
[PMID: 24405702] |
| SGC-7901 | GI50 |
0.3553 nM
Compound: 3
|
Growth inhibition of human SGC7901 cells by MTT assay
Growth inhibition of human SGC7901 cells by MTT assay
|
[PMID: 24405702] |
| U-937 | GI50 |
0.5391 nM
Compound: 3
|
Growth inhibition of human U937 cells by MTT assay
Growth inhibition of human U937 cells by MTT assay
|
[PMID: 24405702] |
The cytotoxicity of cabazitaxel (100 μg/mL) on 4T1 cells without irradiation is 70.8%. Cabazitaxel (100 μg/mL) exhibits a concentration-dependent antiproliferation effect, with the antiproliferative activity of 56.2%[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 183133-96-2
-
Appearance Solid
-
Masse moléculaire 835.93
-
Formule C45H57NO14
-
Color White to off-white
-
SMILES
CC1=C([C@@H](OC)C([C@@]2(C)[C@@]3([H])[C@](OC(C)=O)(CO4)[C@H]4C[C@@H]2OC)=O)C(C)(C)[C@@]([C@H]3OC(C5=CC=CC=C5)=O)(O)C[C@@H]1OC([C@H](O)[C@H](C6=CC=CC=C6)NC(OC(C)(C)C)=O)=O
-
Synonyms
XRP6258; RPR-116258A; taxoid XRP6258
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (26)
-
Journal Impact Factor
-
Most Recent
-
Eur Urol
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. [Abstract]2020 Nov 2;S0302-2838(20)30778-8. PMID: 33153817 -
J Clin Invest
Targeting Wnt/β-Catenin and circadian regulator restores PRC2/EZH2 controlled chromatin bivalency and suppresses cell state diversity. [Abstract]2026 Mar 17:e200260. PMID: 41842971 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 2:102053. PMID: 40187357 -
Proc Natl Acad Sci U S A
Chlamydomonas protein kinase MAK phosphorylates FAP256/CEP104 and regulates axonemal microtubule assembly. [Abstract]2025 Nov 18;122(46):e2503094122. PMID: 41231942
Cabazitaxel purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2025 Nov 18;122(46):e2503094122. [Abstract]
Cabazitaxel (25 μM; 8 h) treatment partially rescues the ciliary phenotype of mak-1. Shown are DIC images of mak-1 cells after treatment with Cabazitaxel.
-
Pharmaceutics
Cabazitaxel-Loaded Nanoparticles Reduce the Invasiveness in Metastatic Prostate Cancer Cells: Beyond the Classical Taxane Function. [Abstract]2023 Feb 16;15(2):662. PMID: 36839985
Cabazitaxel purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2023 Feb 16;15(2):662. [Abstract]
Cell viability in C4-2B cell line. The 48 h IC50 values in C4-2B cells are as follows: Cabazitaxel (CBZ), 2.8 nM; NT CBZ NP, 24.5 nM; T CBZ NP, 10.52 nM. The 72 h IC50 values are: CBZ, 4.96; NT CBZ NP, 1.81 nM; T CBZ NP, 5.21 nM (95% confidence intervals (CI)); n = 3.
Cabazitaxel purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2023 Feb 16;15(2):662. [Abstract]
Transwell Invasion Assay indicated that cell invasion was limited with Cabazitaxel (CBZ, 2.5 nM) and CBZ NP with respect to control after 24 h of treatment.
Cabazitaxel purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2023 Feb 16;15(2):662. [Abstract]
IL-8 mRNA expression was lower in Cabazitaxel (CBZ) and CBZ-loaded NPs at sub-IC50 (2.5 nM; 6 h) concentrations compared to control.
-
ACS Appl Nano Mater
2019 Oct 25;2(10):6249-6257. PMID: 33585803
Cabazitaxel purchased from MedChemExpress. Usage Cited in: ACS Appl Nano Mater. 2019 Oct 25;2(10):6249-6257. [Abstract]
MTT cell viability assay after treatment with increasing concentrations (0.2–20.0 μg/mL Cabazitaxel loaded) of BiNP or P-BiNP resulting in decreased cell viability of P-BiNPs at equivalent treatment dosage as BiNPs after 72 h.
-
-
RSC Adv
Three-in-one: exploration of co-encapsulation of cabazitaxel, bicalutamide and chlorin e6 in new mixed cyclodextrin-crosslinked polymers. [Abstract]2023 Apr 6;13(16):10923-10939. PMID: 37033421 -
Nanomedicine (Lond)
Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. [Abstract]2017 Sep;12(17):2083-2095. PMID: 28805551 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Mol Pharm
2022 Nov 7;19(11):4320-4332. PMID: 36269563 -
Sci Rep
Investigation of enzalutamide, docetaxel, and cabazitaxel resistance in the castration resistant prostate cancer cell line C4 using genome-wide CRISPR/Cas9 screening. [Abstract]2023 Jun 3;13(1):9043. PMID: 37270558 -
J Pharm Sci
Insights into interactions between taxanes and P-glycoprotein using biophysical and in silico methods. [Abstract]2025 May;114(5):103708. PMID: 40015511 -
Cardiovasc Toxicol
The Potential Protective Effects of Resveratrol Against Cabazitaxel-Induced Oxidative Stress and Cardiotoxicity in Rats. [Abstract]2026 May 27;26(6):61. PMID: 42192024 -
Bioengineering (Basel)
Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]2025 Oct 19;12(10):1121. PMID: 41155119 -
Cancer Manag Res
Antitumor Activity of Cabazitaxel and MSC-TRAIL Derived Extracellular Vesicles in Drug-Resistant Oral Squamous Cell Carcinoma. [Abstract]2020 Oct 29;12:10809-10820. PMID: 33149686 -
PLoS One
The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells. [Abstract]2020 Jun 2;15(6):e0234078. PMID: 32484838 -
Prostate
Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity. [Abstract]2018 Sep;78(12):905-914. PMID: 29749077 -
Prostate
2018 Feb;78(3):166-177. PMID: 29181846
Cabazitaxel purchased from MedChemExpress. Usage Cited in: Prostate. 2018 Feb;78(3):166-177. [Abstract]
Western blot analysis of apoptosis marker PARP in stable cell lines treated with 50 or 100 nM Cabazitaxel.
-
-
-
-
-
Methods Mol Biol
2018:1711:351-398. PMID: 29344898 -
Oncotarget
Brachyury as a potential modulator of androgen receptor activity and a key player in therapy resistance in prostate cancer. [Abstract]2016 May 17;7(20):28891-902. PMID: 27049720
Cabazitaxel purchased from MedChemExpress. Usage Cited in: Oncotarget. 2016 May 17;7(20):28891-902. [Abstract]
Western blot analyses for Brachyury and AR expression in prostate cell lines treated with Docetaxel (Doc) or with Cabazitaxel (Cab). Graphs represent the densimetric semi-quantification of western blot images.
-
Chin J Cancer
ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel. [Abstract]2015 Mar 5;34(3):115-20. PMID: 25962593
Solvant et solubilité
DMSO : ≥ 100 mg/mL (119.63 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.99 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.99 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
The cytotoxicity of CBX-loaded ANs and free Cabazitaxel (CBX) is evaluated with MTT assay. Cells are seeded onto a 96-well plate at a density of 3000 cells per well and cultured for 24 h. CBX-loaded ANs and free CBX are diluted to predetermined concentrations with PBS and added into each well. Blank AN, AN-ICG and free CBX solvent (a mixture of Tween-80 and anhydrous alcohol) are added as well to different final concentrations. The incubation continued for another 48 hours. 20 µL MTT solutions (5 mg/mL in PBS) are added into each well and cells are incubated for another 4 hours under 37°C. Subsequently the medium is removed and 150 µL dimethyl sulphoxide (DMSO) is added to dissolve the purple formazan salt crystals. Then the absorbance is measured by a microplate reader at 490 nm. The cells treated with medium are evaluated as controls.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
To evaluate the antitumor efficiency of the combined chemotherapy and PTT in vivo, mice bearing 4T1 tumor are randomLy divided into 6 treatment groups (n=5). Treatment begin when the tumors reached 50 mm3-100 mm3. The mice are intravenously injected with saline, AN-ICG, free Cabazitaxel (CBX), AN-CBX and AN-ICG-CBX (ICG 2 mg/kg, CBX 10 mg/kg). 8 hours later, the groups injected with AN-ICG and AN-ICG-CBX is irradiated by the 808 nm laser (0.8 W/cm2, 5 min). The length and width of every tumor are measured by a caliper every other day. The formula (volume (mm3) =1/2 × length × width2) is used to calculate the tumor volume. The body weights of these mice are recorded every two days using an electronic balance as well. At the end of the antitumor study, the 4T1 tumor bearing mice are sacrificed to collect the tumors and major organs.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (286 KB)
-
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Portuguese - PT (557 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Tai X, et al. Cabazitaxel and indocyanine green co-delivery tumor-targeting nanoparticle for improved antitumor efficacy and minimized drug toxicity. J Drug Target. 2016 Sep 9:1-29. [Content Brief]
[2]. Gdowski AS, et al. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. Nanomedicine (Lond). 2017 Sep;12(17):2083-2095. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.1963 mL | 5.9814 mL | 11.9627 mL | 29.9068 mL |
| 5 mM | 0.2393 mL | 1.1963 mL | 2.3925 mL | 5.9814 mL | |
| 10 mM | 0.1196 mL | 0.5981 mL | 1.1963 mL | 2.9907 mL | |
| 15 mM | 0.0798 mL | 0.3988 mL | 0.7975 mL | 1.9938 mL | |
| 20 mM | 0.0598 mL | 0.2991 mL | 0.5981 mL | 1.4953 mL | |
| 25 mM | 0.0479 mL | 0.2393 mL | 0.4785 mL | 1.1963 mL | |
| 30 mM | 0.0399 mL | 0.1994 mL | 0.3988 mL | 0.9969 mL | |
| 40 mM | 0.0299 mL | 0.1495 mL | 0.2991 mL | 0.7477 mL | |
| 50 mM | 0.0239 mL | 0.1196 mL | 0.2393 mL | 0.5981 mL | |
| 60 mM | 0.0199 mL | 0.0997 mL | 0.1994 mL | 0.4984 mL | |
| 80 mM | 0.0150 mL | 0.0748 mL | 0.1495 mL | 0.3738 mL | |
| 100 mM | 0.0120 mL | 0.0598 mL | 0.1196 mL | 0.2991 mL |
Powered by Bioz